We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
Read MoreHide Full Article
In the latest close session, Bristol Myers Squibb (BMY - Free Report) was up +1.52% at $55.53. The stock's performance was ahead of the S&P 500's daily loss of 1.44%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 2.22%.
The biopharmaceutical company's shares have seen a decrease of 8.01% over the last month, not keeping up with the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on July 30, 2026. In that report, analysts expect Bristol Myers Squibb to post earnings of $1.61 per share. This would mark year-over-year growth of 10.27%. Meanwhile, the latest consensus estimate predicts the revenue to be $11.67 billion, indicating a 4.89% decrease compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $6.32 per share and a revenue of $47.39 billion, demonstrating changes of +2.76% and -1.66%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.06% rise in the Zacks Consensus EPS estimate. Bristol Myers Squibb currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Bristol Myers Squibb has a Forward P/E ratio of 8.65 right now. This represents a discount compared to its industry average Forward P/E of 21.4.
Investors should also note that BMY has a PEG ratio of 0.16 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.47.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 156, finds itself in the bottom 37% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
In the latest close session, Bristol Myers Squibb (BMY - Free Report) was up +1.52% at $55.53. The stock's performance was ahead of the S&P 500's daily loss of 1.44%. Elsewhere, the Dow lost 0.09%, while the tech-heavy Nasdaq lost 2.22%.
The biopharmaceutical company's shares have seen a decrease of 8.01% over the last month, not keeping up with the Medical sector's gain of 0.57% and the S&P 500's gain of 0.08%.
Market participants will be closely following the financial results of Bristol Myers Squibb in its upcoming release. The company plans to announce its earnings on July 30, 2026. In that report, analysts expect Bristol Myers Squibb to post earnings of $1.61 per share. This would mark year-over-year growth of 10.27%. Meanwhile, the latest consensus estimate predicts the revenue to be $11.67 billion, indicating a 4.89% decrease compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $6.32 per share and a revenue of $47.39 billion, demonstrating changes of +2.76% and -1.66%, respectively, from the preceding year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Bristol Myers Squibb. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, there's been a 0.06% rise in the Zacks Consensus EPS estimate. Bristol Myers Squibb currently has a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Bristol Myers Squibb has a Forward P/E ratio of 8.65 right now. This represents a discount compared to its industry average Forward P/E of 21.4.
Investors should also note that BMY has a PEG ratio of 0.16 right now. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. By the end of yesterday's trading, the Medical - Biomedical and Genetics industry had an average PEG ratio of 1.47.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 156, finds itself in the bottom 37% echelons of all 250+ industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.